Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Cancer Res. 2018 Jun 11;78(15):4370–4385. doi: 10.1158/0008-5472.CAN-17-3993

Figure 6. Licofelone significantly improves paclitaxel efficacy in an ovarian cancer PDX mouse model.

Figure 6

(A) Graphical representation of PDX development and treatment timeline. (B) Kaplan-Meyer survival curve for each arm of therapy: vehicle (black, n=7), 12 mg/kg paclitaxel (red, n=7), 50 mg/ kg licofelone (blue, n=7), and 12 mg/kg paclitaxel + 50 mg/kg licofelone (green, n=8). Median survival was significantly higher in the combination group (~141days, p< 0.05), compared to paclitaxel alone (115 days), licofelone alone (37 days), or vehicle (30 days). (C) Expression of stem-like genes (ALDH1A, CD133) is increased in paclitaxel PDX tumors at the time of sacrifice while licofelone treatment inhibits the induction (n=4, p< 0.05, Two-way ANOVA).

HHS Vulnerability Disclosure